US › Healthcare

PAVmed Inc (PAVM)

US · Healthcare · Medical Devices

$3.97+1.28%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

$33,000

Revenue YoY

+450.0%

Net profit

$-5.4M

EPS

$-0.42

EPS estimate

$-0.66

Net margin

-16,315.2%

EPS came in at -0.42 against a street estimate of -0.66 — a beat of 36.4%.

Key statistics

Market cap

$38.6M

Forward P/E

0.0

P/B

1.24

Book value

$4.98

EPS (TTM)

$-17.03

52-week high

$17.99

52-week low

$3.70

50-day MA

$5.06

200-day MA

$7.54

Beta

0.54

Analyst view

Analysts rate PAVmed Inc a strong buy (2 buy, 0 hold, 0 sell out of 2) with an average price target of $36.50.

Shareholding

Insiders

41.44%

Institutions

26.26%

Largest institutional holders

Fund	Stake
Two Seas Capital LP	6.45%
First Manhattan Co. LLC	0.33%
Geode Capital Management, LLC	0.16%
Vanguard Capital Management, LLC	0.08%
Vanguard Fiduciary Trust Co	0.08%
BlackRock Inc	0.03%
Tower Research Capital LLC	0.01%
Morgan Stanley - Brokerage Accounts	0.00%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for PAVmed Inc — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.